The cost-effectiveness of screening mammography beyond age 65 years: a systematic review for the U.S. Preventive Services Task Force.

Jeanne Mandelblatt, Somnath (Som) Saha, Steven Teutsch, Tom Hoerger, Albert L. Siu, David Atkins, Jonathan Klein, Mark Helfand

Research output: Contribution to journalArticle

99 Citations (Scopus)

Abstract

PURPOSE: There are few data on the effects of disease biology and competing mortality on the effectiveness of screening women for breast cancer after age 65 years. The authors performed a review to determine the costs and benefits of mammography screening after age 65 years. DATA SOURCES: Cost-effectiveness articles published between January 1989 and March 2002. STUDY SELECTION: Studies were identified by using MEDLINE and the National Health Service Economic Evaluation Database. The authors included research on screening after age 65 years conducted from a societal or government perspective; reviews and analyses of other technologies were excluded. DATA SYNTHESIS: 115 studies were identified and 10 met inclusion criteria. One study modeled age-dependent assumptions of disease biology. No study fully captured the potential harms of screening, including anxiety associated with false-positive results, overdiagnosis, and previous knowledge of cancer or living longer with the consequences of treatment. Studies differed in the specific strategies compared and in analytic approaches. On average, extending biennial screening to age 75 or 80 years was estimated to cost 34 000 dollars to 88 000 dollars (2002 U.S. dollars) per life-year gained, compared with stopping screening at age 65 years. Two studies suggested that it was more cost-effective to target healthy women than those with several competing risks for death. CONCLUSIONS: Current estimates suggest that biennial breast cancer screening after age 65 years reduces mortality at reasonable costs for women without clinically significant comorbid conditions. More data are needed on disease biology and preferences for benefits and harms in older women.

Original languageEnglish (US)
Pages (from-to)835-842
Number of pages8
JournalAnnals of Internal Medicine
Volume139
Issue number10
StatePublished - Nov 18 2003
Externally publishedYes

Fingerprint

Advisory Committees
Mammography
Cost-Benefit Analysis
Costs and Cost Analysis
Breast Neoplasms
Mortality
Health Services Research
National Health Programs
Early Detection of Cancer
MEDLINE
Anxiety
Databases
Technology
Research
Neoplasms
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

The cost-effectiveness of screening mammography beyond age 65 years : a systematic review for the U.S. Preventive Services Task Force. / Mandelblatt, Jeanne; Saha, Somnath (Som); Teutsch, Steven; Hoerger, Tom; Siu, Albert L.; Atkins, David; Klein, Jonathan; Helfand, Mark.

In: Annals of Internal Medicine, Vol. 139, No. 10, 18.11.2003, p. 835-842.

Research output: Contribution to journalArticle

Mandelblatt, Jeanne ; Saha, Somnath (Som) ; Teutsch, Steven ; Hoerger, Tom ; Siu, Albert L. ; Atkins, David ; Klein, Jonathan ; Helfand, Mark. / The cost-effectiveness of screening mammography beyond age 65 years : a systematic review for the U.S. Preventive Services Task Force. In: Annals of Internal Medicine. 2003 ; Vol. 139, No. 10. pp. 835-842.
@article{07fd5f3546744cd1bfee7718bcb1fa40,
title = "The cost-effectiveness of screening mammography beyond age 65 years: a systematic review for the U.S. Preventive Services Task Force.",
abstract = "PURPOSE: There are few data on the effects of disease biology and competing mortality on the effectiveness of screening women for breast cancer after age 65 years. The authors performed a review to determine the costs and benefits of mammography screening after age 65 years. DATA SOURCES: Cost-effectiveness articles published between January 1989 and March 2002. STUDY SELECTION: Studies were identified by using MEDLINE and the National Health Service Economic Evaluation Database. The authors included research on screening after age 65 years conducted from a societal or government perspective; reviews and analyses of other technologies were excluded. DATA SYNTHESIS: 115 studies were identified and 10 met inclusion criteria. One study modeled age-dependent assumptions of disease biology. No study fully captured the potential harms of screening, including anxiety associated with false-positive results, overdiagnosis, and previous knowledge of cancer or living longer with the consequences of treatment. Studies differed in the specific strategies compared and in analytic approaches. On average, extending biennial screening to age 75 or 80 years was estimated to cost 34 000 dollars to 88 000 dollars (2002 U.S. dollars) per life-year gained, compared with stopping screening at age 65 years. Two studies suggested that it was more cost-effective to target healthy women than those with several competing risks for death. CONCLUSIONS: Current estimates suggest that biennial breast cancer screening after age 65 years reduces mortality at reasonable costs for women without clinically significant comorbid conditions. More data are needed on disease biology and preferences for benefits and harms in older women.",
author = "Jeanne Mandelblatt and Saha, {Somnath (Som)} and Steven Teutsch and Tom Hoerger and Siu, {Albert L.} and David Atkins and Jonathan Klein and Mark Helfand",
year = "2003",
month = "11",
day = "18",
language = "English (US)",
volume = "139",
pages = "835--842",
journal = "Annals of Internal Medicine",
issn = "0003-4819",
publisher = "American College of Physicians",
number = "10",

}

TY - JOUR

T1 - The cost-effectiveness of screening mammography beyond age 65 years

T2 - a systematic review for the U.S. Preventive Services Task Force.

AU - Mandelblatt, Jeanne

AU - Saha, Somnath (Som)

AU - Teutsch, Steven

AU - Hoerger, Tom

AU - Siu, Albert L.

AU - Atkins, David

AU - Klein, Jonathan

AU - Helfand, Mark

PY - 2003/11/18

Y1 - 2003/11/18

N2 - PURPOSE: There are few data on the effects of disease biology and competing mortality on the effectiveness of screening women for breast cancer after age 65 years. The authors performed a review to determine the costs and benefits of mammography screening after age 65 years. DATA SOURCES: Cost-effectiveness articles published between January 1989 and March 2002. STUDY SELECTION: Studies were identified by using MEDLINE and the National Health Service Economic Evaluation Database. The authors included research on screening after age 65 years conducted from a societal or government perspective; reviews and analyses of other technologies were excluded. DATA SYNTHESIS: 115 studies were identified and 10 met inclusion criteria. One study modeled age-dependent assumptions of disease biology. No study fully captured the potential harms of screening, including anxiety associated with false-positive results, overdiagnosis, and previous knowledge of cancer or living longer with the consequences of treatment. Studies differed in the specific strategies compared and in analytic approaches. On average, extending biennial screening to age 75 or 80 years was estimated to cost 34 000 dollars to 88 000 dollars (2002 U.S. dollars) per life-year gained, compared with stopping screening at age 65 years. Two studies suggested that it was more cost-effective to target healthy women than those with several competing risks for death. CONCLUSIONS: Current estimates suggest that biennial breast cancer screening after age 65 years reduces mortality at reasonable costs for women without clinically significant comorbid conditions. More data are needed on disease biology and preferences for benefits and harms in older women.

AB - PURPOSE: There are few data on the effects of disease biology and competing mortality on the effectiveness of screening women for breast cancer after age 65 years. The authors performed a review to determine the costs and benefits of mammography screening after age 65 years. DATA SOURCES: Cost-effectiveness articles published between January 1989 and March 2002. STUDY SELECTION: Studies were identified by using MEDLINE and the National Health Service Economic Evaluation Database. The authors included research on screening after age 65 years conducted from a societal or government perspective; reviews and analyses of other technologies were excluded. DATA SYNTHESIS: 115 studies were identified and 10 met inclusion criteria. One study modeled age-dependent assumptions of disease biology. No study fully captured the potential harms of screening, including anxiety associated with false-positive results, overdiagnosis, and previous knowledge of cancer or living longer with the consequences of treatment. Studies differed in the specific strategies compared and in analytic approaches. On average, extending biennial screening to age 75 or 80 years was estimated to cost 34 000 dollars to 88 000 dollars (2002 U.S. dollars) per life-year gained, compared with stopping screening at age 65 years. Two studies suggested that it was more cost-effective to target healthy women than those with several competing risks for death. CONCLUSIONS: Current estimates suggest that biennial breast cancer screening after age 65 years reduces mortality at reasonable costs for women without clinically significant comorbid conditions. More data are needed on disease biology and preferences for benefits and harms in older women.

UR - http://www.scopus.com/inward/record.url?scp=0642303164&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0642303164&partnerID=8YFLogxK

M3 - Article

C2 - 14623621

AN - SCOPUS:0642303164

VL - 139

SP - 835

EP - 842

JO - Annals of Internal Medicine

JF - Annals of Internal Medicine

SN - 0003-4819

IS - 10

ER -